Results 101 to 110 of about 126,909 (281)

Gut microbiota‐related modulation of immune mechanisms in post‐infarction remodelling and heart failure

ESC Heart Failure, Volume 12, Issue 2, Page 942-954, April 2025.
Abstract The immune system has long been recognized as a key driver in the progression of heart failure (HF). However, clinical trials targeting immune effectors have consistently failed to improve patient outcome across different HF aetiologies. The activation of the immune system in HF is complex, involving a broad network of pro‐inflammatory and ...
Johann Roessler, Friederike Zimmermann, Bettina Heidecker, Ulf Landmesser, Arash Haghikia   +4 more
wiley   +1 more source

Myogenic differentiation of VCP disease-induced pluripotent stem cells: A novel platform for drug discovery. [PDF]

PLoS ONE, 2017
Valosin Containing Protein (VCP) disease is an autosomal dominant multisystem proteinopathy caused by mutations in the VCP gene, and is primarily associated with progressive muscle weakness, including atrophy of the pelvic and shoulder girdle muscles ...
Katrina J Llewellyn, Angèle Nalbandian, Lan N Weiss, Isabela Chang, Howard Yu, Bibo Khatib, Baichang Tan, Vanessa Scarfone, Virginia E Kimonis   +8 more
doaj   +1 more source

Metabolic syndrome influences cardiac gene expression pattern at the transcript level in male ZDF rats [PDF]

, 2013
Background: Metabolic syndrome (coexisting visceral obesity, dyslipidemia, hyperglycemia, and hypertension) is a prominent risk factor for cardiovascular morbidity and mortality, however, its effect on cardiac gene expression pattern is unclear ...
Csonka, Csaba, Csont, Tamás Bálint, Fekete, Veronika, Ferdinandy, Péter, Gyémánt, Nóra, Kocsis-Fodor, Gabriella, Pipis, Judit, Puskás, László, Szűcs, Gergő, Sárközy, Márta, Zvara, Ágnes   +10 more
core   +3 more sources

A First in Human Study of the Selective Cardiac Myosin Inhibitor, CK-3773274 [PDF]

Journal of Cardiac Failure, 2019
Introduction Hypercontractility of the cardiac sarcomere appears to underlie pathological hypertrophy and fibrosis in select genetic hypertrophic cardiomyopathies (HCM). CK-3773274 (CK-274) decreases systolic function in preclinical models by directly binding to the cardiac myosin motor domain and inhibiting the myosin ATPase, stabilizing the motor in
Laura A. Robertson, Danielle R. Armas, Edward Robbie, Anna Osmukhina, Hanbin Li, Fady I. Malik, Scott D. Solomon   +6 more
openaire   +1 more source

Cardiac remodelling in the era of the recommended four pillars heart failure medical therapy

ESC Heart Failure, Volume 12, Issue 2, Page 1029-1044, April 2025.
Abstract Cardiac remodelling is a key determinant of worse cardiovascular outcome in patients with heart failure (HF) and reduced ejection fraction (HFrEF). It affects both the left ventricle (LV) structure and function as well as the left atrium (LA) and the right ventricle (RV).
Giada Colombo, Tor Biering‐Sorensen, Joao P. Ferreira, Carlo Mario Lombardi, Andrea Bonelli, Andrea Garascia, Marco Metra, Riccardo M. Inciardi   +7 more
wiley   +1 more source

Hypertrophic Cardiomyopathy as a Form of Heart Failure with Preserved Ejection Fraction: Diagnosis, Drugs, and Procedures

US Cardiology Review
Hypertrophic cardiomyopathy (HCM) is a complex and heterogeneous cardiac disorder characterized by cardiac hypertrophy disproportionate to loading stimuli (e.g. hypertension or aortic stenosis).
Sukriti Banthiya, Larissa Check, Jessica Atkins   +2 more
doaj   +1 more source

The effects of sodium–glucose cotransporter 2 inhibitors on the ‘forgotten’ right ventricle

ESC Heart Failure, Volume 12, Issue 2, Page 1045-1058, April 2025.
Abstract With the progress in diagnosis, treatment and imaging techniques, there is a growing recognition that impaired right ventricular (RV) function profoundly affects the prognosis of patients with heart failure (HF), irrespective of their left ventricular ejection fraction (LVEF).
Liangzhen Qu, Xueting Duan, Han Chen
wiley   +1 more source

Considerations for drug trials in hypertrophic cardiomyopathy

ESC Heart Failure, Volume 12, Issue 2, Page 1095-1112, April 2025.
Abstract Hypertrophic cardiomyopathy (HCM) is a heterogeneous condition with potentially serious manifestations. Management has traditionally comprised therapies to palliate symptoms and implantable cardioverter‐defibrillators to prevent sudden cardiac death. The need for disease‐modifying therapies has been recognized for decades.
John P. Farrant, Matthias Schmitt, Anna B. Reid, Clifford J. Garratt, William G. Newman, Aneil Malhotra, Rhys Beynon, Masliza Mahmod, Betty Raman, Robert M. Cooper, Dana Dawson, Thomas Green, Sanjay K. Prasad, Anvesha Singh, Susanna Dodd, Hugh Watkins, Stefan Neubauer, Christopher A. Miller   +17 more
wiley   +1 more source

Atrial remodelling and dysfunction in hypertrophic cardiomyopathy: prognostic role and therapeutic target

Frontiers in Cardiovascular Medicine
IntroductionHypertrophic cardiomyopathy (HCM) is a common genetic cardiac disease marked by abnormal ventricular hypertrophy. Recent studies have highlighted that left atrial (LA) remodelling—including dilation, fibrosis, and functional impairment—plays ...
Chiara Piazzai, Alessio Petrone, Andrea Stefanini, Flavio D’Ascenzi, Iacopo Olivotto, Iacopo Olivotto, Matteo Cameli   +6 more
doaj   +1 more source

Calcium sensitizers: What have we learned over the last 25years? [PDF]

, 2018
K
Papp, Gy. Julius, Papp, Zoltán, Pollesello, Piero   +2 more
core   +1 more source